Promacta OK’d in severe aplastic anemia
This article was originally published in Scrip
Executive Summary
The FDA granted its blessing for GlaxoSmithKline to market Promacta (eltrombopag) as a treatment in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy (IST).